More information
Description
Oncochain Solutions SRL, a Romanian start-up founded in 2019, is undertaking a groundbreaking project focused on enhancing its software solutions for oncology service providers. This venture aims to elevate the accuracy and quality of medical data, facilitating more effective and personalized cancer therapies. The long-term vision includes generating data sets and analytics, empowering researchers, doctors, and pharmaceutical companies to predict cancer probabilities and develop new risk biomarkers. With a robust focus on innovation, this project presents a high degree of profitability and feasibility. It aligns with the "SMEs Growth Romania" program''s objective of fostering business growth in start-ups while contributing to improved healthcare outcomes.
The primary aim of this project is to develop, test, and validate the Oncochain technology platform. This platform integrates cutting-edge technologies, including AI, machine learning, NLP (Natural Language Processing), and OCR (Optical Character Recognition). The goal is to create a disruptive and innovative solution for analyzing, managing, extracting, and modeling real-world oncology data. By harnessing the power of these advanced technologies, the project aims to have a significant impact by implementing adaptive personalized care for cancer patients.
The project plans to achieve these aims through a variety of key activities, including:
- Project and Financial Management
- Project Publicity
- Acquiring Legal Expertise Services for other EU Markets
- Participation in Thematic Conferences
Summary of project results
The project aimed to address several key issues and challenges faced by the Applicant Firstly, there was a need to enhance the accuracy and quality of medical data to improve the efficiency and efficacy of personalized cancer therapies. The existing solution required advanced capabilities to achieve this goal. Additionally, the project sought to generate data sets and analytics, as well as modeling frameworks, to help researchers, doctors, and pharmaceutical companies predict cancer probabilities and develop new risk biomarkers, ultimately improving the prevention rate.
One of the significant challenges was the lack of appropriately skilled resources for Natural Language Processing (NLP) development. Another challenge was the labor-intensive process of acquiring data. The development of Optical Character Recognition (OCR) and API modules aimed to reduce the manual labor required for data curation, allowing clinical data managers to focus on high-value activities such as advanced analytics and statistics.
Overall, the project aimed to develop, test, and validate the applicant technology platform, integrating cutting-edge technologies like AI, machine learning, NLP, and OCR to create a disruptive and innovative solution for analyzing, managing, extracting, and modeling real-world oncology data.
Key activities included developing OCR algorithms for medical text identification and de-identification, creating NLP models for various medical reports, and updating the platform software to integrate these capabilities. The project also involved purchasing OCR scanners, managing cloud environment costs, and conducting project and financial management. Publicity activities, clinical data management, participation in thematic conferences, acquiring legal expertise for other EU markets, and a financial audit were also part of the project.
The project successfully developed an innovative real-world data platform in oncology, upgraded it with OCR, machine learning, and NLP capabilities, and achieved significant advancements in analyzing and managing oncology data.
The innovative real-world data platform in oncology, upgraded with OCR, machine learning, and NLP capabilities, provided significant advancements in analyzing and managing oncology data. This, in turn, benefited oncology service providers, researchers, doctors, and pharmaceutical companies by offering improved tools for data collection, standardization, and analytics. Ultimately, cancer patients benefited from more effective and personalized cancer therapies, contributing to better healthcare outcomes.